Shengfeng Li founded Bio-Thera in 2003, and has served since that time as Chief Executive Officer and as a member of our Board of Directors. Prior to founding Bio-Thera, Dr. Li was a founder and founding Chief Scientific Officer of Abmaxis, Inc., which was acquired by Merck. Prior to co-founding Abmaxis, he was employed at COR Therapeutics (merged with Millennium Pharmaceuticals). Dr. Li received his Ph.D. in Microbiology from the University of Georgia in 1991; afterwards, he worked as a postdoctoral scientist and later as a Donoghue Foundation fellow at Yale, where he identified several Raf kinase signaling regulatory molecules such as RKIP and the 14-3-3 family of proteins. Dr. Li is an author on multiple publications in peer reviewed journals including Nature, EMBO, Gene & Dev, and PNAS. He is an inventor on over 20 patents in the areas of target identification, drug discovery, antibody engineering, and product development.
Jinchen Yu, Senior Vice President, Preclinical Research
Dr. Jinchen Yu is currently Senior Vice President of Bio-Thera, leading research operations and preclinical development. Dr. Yu is an expert on cancer biology and has over 25 years of biotechnology experience with hands-on involvement in all stages of drug development. Before joining Bio-Thera in January 2013, he worked at COR Therapeutics, Millennium Pharmaceuticals, NexGenix Pharmaceuticals and Crown Bioscience, with increasing responsibilities. He has led several cancer antibody drug projects and two kinase inhibitor projects from early phase to clinical stage. He has more than 40 publications in peer-reviewed journals, including 10 first author papers, as well as several patents. Dr. Yu received his Ph.D. in Molecular Biology from Florida State University, and conducted postdoctoral research at the National Cancer Institute of the National Institutes of Health, USA, working on signal pathways of growth factor and receptor tyrosine kinases.
Chloe Liu, Senior Vice President, Technology Development
Dr. Chloe Liu currently is Senior Vice President of Bio-Thera Solutions, responsible for leading technical operation teams, including process development, formulation development, analytical development, and related pharmaceutical development strategies. Prior to Bio-Thera, Dr. Liu has gained over 20 years of biotech/ biopharmaceutical industry experience at formerly Wyeth now Pfizer, formerly Momenta now J&J, Biomabs, Huahai, Alphamab, and Hepalink, where she held roles from technical leader to senior executive management. Over the course of her career, Dr. Liu has led and managed CMC development for more than 50 complex mixture products of non-biologics and biologics across the IND and NDA phases, several of which have obtained US/EU/China marketing approvals. Dr. Liu has over 25 international peer-reviewed publications and is an inventor of 15 patents. She received a Ph.D. in Biophysical Chemistry from the University of Western Ontario, Canada, and completed her postdoc training at the University of Massachusetts at Amherst, USA.
Xianming Huang, Senior Vice President, Discovery Research
Dr. Xianming Huang is currently Senior Vice President of Bio-Thera, leading the research and development of novel antibody therapeutics and innovative technology platform. Dr. Huang has 30 years of experience in the successful discovery and development of antibody therapeutics across many biologic modalities. Prior to joining Bio-Thera Solutions, he served as a director at Avid Bioservices, Inc. and was responsible for the research and development of antibody therapeutics. Prior to that, he was an assistant professor of the University of Texas Southwestern Medical Center (UTSW). Dr. Huang has authored over 20 publications in peer reviewed journals, including Science and Cancer Research. He was an invited speaker in various international conferences, including AACR annual meeting, Keystone Symposia, and Gordon Research Conference. He has over 20 issued and pending international patents. Dr. Huang received his doctorate degree from Peking Union Medical College in 1993, and completed his postdoctoral training at UTSW.
Bert Thomas, Senior Vice President, Business Development
Dr. Bert Thomas has over 25 years of experience in the healthcare space, including experience in drug discovery, business development & licensing, strategic alliances and patient advocacy. Prior to joining Bio-Thera Solutions, Dr. Thomas was the Chief Executive Officer of the Sarcoma Foundation of America (SFA), an organization focused on funding sarcoma research and raising awareness of the disease. Before joining the SFA, Dr. Thomas held the positions of Director, Corporate Alliances and Interim Head of Development at the American Association of Cancer Research (AACR). Prior to the AACR, Dr. Thomas held positions of progressive leadership in Research and Development and Business Development for over 18 years in the pharmaceutical industry, working for Genetics Institute, Wyeth, MGI Pharma, Adolor Corporation, Guilford Pharmaceuticals and Procept. Dr. Thomas holds a Ph.D. from the University of California, Los Angeles, and an MBA from Johns Hopkins University. Dr. Thomas has authored over 24 publications in peer reviewed journals and 2 book chapters.
Lan Mu, Senior Vice President, Regulatory Affairs
Dr. Lan Mu has over 20 years of experience in medicinal product discovery, development and global registration in various therapeutic areas. She was a principal research investigator at Sanofi prior to earning her Regulatory Affairs Certification (RAC). Subsequently, she held roles of increasing responsibility at Celgene, Vanotech and Bio-Thera, and has led global regulatory affairs teams, developing and implementing regulatory strategies for clinical and commercial registrations and their life cycle management in the US, EU, Canada, Japan and ROW countries. Lan received her Ph.D. in Physical Chemistry from the University of Florida and completed her postdoctoral research at the National Cancer Institute (NCI, NIH, USA); She developed and conducted regulatory trainings for the Regulatory Affairs Professionals Society (RAPS), chaired Drug Information Association (DIA) Global and Pharmaceutical Regulatory Affairs Asia annual meeting sessions, and published in and served as a reviewer for peer-reviewed journals.
Wenrong Huang, Vice President, Intellectual Property
Wenrong Huang is Vice President, Intellectual Property, of Bio-Thera Solutions. Ms. Huang has over 14 years of legal experience both as an in-house attorney and in law firms, including international law firms Foley & Lardner LLP and Sheppard, Mullin, Richter & Hampton LLP, where her practice focused on worldwide patent prosecution in the fields of chemical, pharmaceutical, life science, and medical device, and client counseling with regard to IP related legal matters. As a research chemist at a leading biopharmaceutical company prior to her legal career, Ms. Huang has many years of industrial experience in designing and synthesizing novel organic molecules as potential drug candidates, and is an inventor and coauthor of a number of patents and peer-reviewed articles. Ms. Huang received her J.D. from UC Hastings College of the Law, and M.S. in chemistry from the University of Michigan.
Ms. Yu Dan Executive Director and the secretary to the Board
Yu Dan has been the secretary to the Board of Bio-Thera Solutions from 2015 and served as the Director since 2016 and re-designated as executive Director in 2020. Primarily, she is responsible for legal compliance and governance of company. She has above 10 years of experience in the corporate compliance field. She has served as a representative of securities affairs, an assistant to the chairman of the Board and the chairman of the supervisory board of Hedy Holdings from 2011 to 2015. She got master degree in human resources, Brunel University.
Bao Cai, Vice President, Biomanufacturing
Mr. Bao Cai is currently serving as Vice President, Biomanufacturing in the company, and is responsible for the management and operation of all bio-manufacturing related projects. Since 2010, Mr. Bao Cai has been engaged in the overall process of biological product production from process development to process validation and to commercial production management. Mr. Bao Cai has served as process engineer, supervisor, person in charge of pilot production, senior director of production and operation and other positions leading the successful launch of several monoclonal antibody products. Mr. Bao Cai has obtained a master's degree from Jinan University, published several articles, and also obtained 6 invention patents.